New Drug Approvals
Firvanq® (vancomycin HCl) Approved for Infectious Diarrhea
Firvanq® (vancomycin hydrochloride) oral solution received U.S. Food and Drug Administration (FDA) approval in January 2018 for the treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Firvanq is the first and only FDA-approved vancomycin oral liquid indicated for C. difficile-associated diarrhea. Each Firvanq kit contains 1 bottle of vancomycin hydrochloride USP powder and 1 bottle of pre-measured grape-flavored diluent for reconstitution by a healthcare provider. Following reconstitution, the concentration of vancomycin is 25 mg/mL or 50 mg/mL supplied in 150 mL, 210 mL, or 300 mL final volumes.